EVOLVE

Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
Tuesday, March 26, 2024
Automation, New Board, The Company, Pressure, ADHD, APAP, Growth, Health, Patient, Chairperson, Tablet, Hospital, Nitric oxide, Successor, NICU, GAAP, Morphine, EVOLVE, Marketing, FDA, Pharmaceutical industry

Adjusted gross profit as a percentage of sales was 62.3% for the fourth quarter of 2023, as compared to 65.9% for the fourth quarter of 2022.

Key Points: 
  • Adjusted gross profit as a percentage of sales was 62.3% for the fourth quarter of 2023, as compared to 65.9% for the fourth quarter of 2022.
  • Mallinckrodt expects fiscal 2024 Acthar Gel net revenue to decline in the low single digits, compared with fiscal 2023.
  • Mallinckrodt received FDA clearance of the INOmax EVOLVE DS Delivery System in the fourth quarter of 2023.
  • Please see the "Reconciliation of Non-GAAP Financial Guidance" included in this release for a reconciliation of GAAP and non-GAAP financial measures for the fourth quarter of 2023 and fiscal 2023.

Guaranteed Rate selects Evocalize to power sophisticated, local digital marketing for Loan Officers to generate new customers and attract referral partners

Retrieved on: 
Wednesday, February 14, 2024
Algorithm, FCC, Marketing, Realtor.com, Rate, EVOLVE, System, Gmail, Martech, Automation, Machine learning, Housing, Partnership

Guaranteed Rate is working with Evocalize to improve the way mortgage loan officers generate leads and get in front of referral partners.

Key Points: 
  • Guaranteed Rate is working with Evocalize to improve the way mortgage loan officers generate leads and get in front of referral partners.
  • The platform will enable local, digital paid marketing to automatically launch targeted programs where buyers and referral partners spend time online, on Google, Facebook, Instagram, TikTok, Gmail and YouTube all at once.
  • "This partnership presents a significant benefit for both Guaranteed Rate and our loan officers," said Guaranteed Rate Chief Marketing Officer, Andrew Pohlmann.
  • To see how Evocalize automates local digital marketing for 1,500,000+ loan officers, real estate agents and local operators to drive real business results, check out our interactive demo at evocalize.com .

SenesTech Announces Exclusive Distribution Agreement and Initial Order for Evolve™ Soft Bait in Singapore

Retrieved on: 
Monday, February 5, 2024
EVOLVE, SenesTech, SNES

PHOENIX, Feb. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announces entry into a Distribution Agreement with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore.

Key Points: 
  • "Agro Technic is a leading manufacturer and supplier for equipment and chemicals in Singapore, with a strong presence in public health vector control, professional pest control and plant protection.
  • The agreement with Agro Technic includes both a substantial initial stocking order and annual minimums.
  • Heng Yiwei, Managing Director of Agro Technic, stated, "Singapore is a city in a garden, the modern metropolis of the region.
  • Agro Technic has been at the forefront of bringing in innovative solutions for the public health sector since the 1970s.

EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing

Retrieved on: 
Wednesday, December 13, 2023
Immunotherapy, Tumor microenvironment, Immunology, Chemistry, CMC, Lead, Therapy, CD2, Society, Control, EVOLVE, Bristol Myers Squibb, ULBP2, SITC, Vaccine

BRANFORD, Conn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today provided a corporate and program update related to the advancement of its pipeline of first-in-category precision immuno-oncology agents. The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.

Key Points: 
  • The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.
  • EvolveImmune intends to use the proceeds from this fundraising to support continued platform and pipeline development including the advancement of its lead multi-functional T-cell engager program, EV-104.
  • “This new capital raise comes at an exciting time for EvolveImmune,” said Stephen Bloch, M.D., chief executive officer of EvolveImmune.
  • The platform also takes advantage the company’s understanding of specific tumor cell characteristics to guide tumor antigen prioritization and program differentiation.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Psychiatry, Quality of life, Medication discontinuation, GEMINI, Evolve, Depression, University, DSM-IV codes, Therapy, Drug, Quality, FRCPC, Annual general meeting, CNS, American College, University of Toronto, EVOLVE, Central nervous system, MDD, Anxiety, Grammatical mood, ASCEND, Pharmaceutical industry

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points: 
  • New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
    NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
  • These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
  • An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
  • “Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

EVOLVE MVMT Launches First Wearable Optimizing Weight Loss Through Walking Form, Tracking Quality of Steps

Retrieved on: 
Friday, November 17, 2023
Other Health, General Health, Mobile, Wireless, Hardware, Consumer Electronics, IOT (Internet of Things), Apps, Applications, Technology, Fitness & Nutrition, Wearables, Mobile Technology, Other Technology, Health, Physical Therapy, Longevity, Research, EVOLVE, Exercise, Spine, Risk, Gait analysis, Cartilage, Patient, Multimedia, Burn, Cleveland Clinic, Joint, Monash University, Movement, Posture, Injury, Burns, Walking, Weight loss, Transport, Mobile phone, MVMT

EVOLVE MVMT , a first-of-its-kind wearable that aims to optimize human movement through walking, is the first to analyze not just quantity, but quality, of steps.

Key Points: 
  • EVOLVE MVMT , a first-of-its-kind wearable that aims to optimize human movement through walking, is the first to analyze not just quantity, but quality, of steps.
  • Created with more than 15 years of research and development, EVOLVE MVMT uses exclusive patented technology to evaluate walking form in real-time.
  • “EVOLVE MVMT utilizes biomimicry to improve neuromuscular performance by increasing muscle activation, which burns more energy,” says Luke Pickett, founder of EVOLVE MVMT.
  • Users start the EVOLVE MVMT journey with a short walking test to understand and identify their own walking pattern.

DISH Upgrades Hotel Entertainment Experience For Guests

Retrieved on: 
Wednesday, November 15, 2023
Android TV, Light-emitting diode, DISH TV, EVOLVE, VESA, M1, SBB, Property management system, Amusement park, Video game, OnStream

Leveraging a user-centric feature set and far more powerful hardware, the EVOLVE M1 provides the best in-room entertainment experience available.

Key Points: 
  • Leveraging a user-centric feature set and far more powerful hardware, the EVOLVE M1 provides the best in-room entertainment experience available.
  • This new SBB seamlessly integrates with the existing suite of DISH Business entertainment solutions.
  • Powered by OnStream and backed by our preeminent experience in the market, the EVOLVE M1 is ready to set a new standard for guest entertainment."
  • This new offering further bolsters the DISH Business array of advanced commercial entertainment products and services.

Groundbreaking Report Outlines Challenges and Opportunities for Professional Interim Executives Leading Nonprofit Organizations, According to Third Sector Company

Retrieved on: 
Tuesday, November 14, 2023
ENTRY, EVOLVE, SPC, Organization, Nonprofit organization, Learning, Social purpose corporation, Consultant, Credentialing, Management, Audit

SEATTLE, Nov. 14, 2023 /PRNewswire/ -- More and more nonprofits around the country are tapping into the power of interim executives as change agents uniquely qualified to prepare their causes for the next chapter of community service under new leadership.

Key Points: 
  • The state of nonprofit boards and their practices are of particular importance to interim leaders as indicators of their readiness to work with and support a new nonprofit leader successfully.
  • "In community organizations, the role of interim leadership is finally receiving its due recognition as a core strategy of succession planning.
  • ADVANCING DIVERSITY & INCLUSION Position the interim executive as a critical intervention for the advancement of diversity, equity, inclusion, and racial justice in nonprofit organizations.
  • Leadership continuity solutions include interim chief executive and chief development officers, succession planning, executive search, and professional development, including learning academies for interim executives , board members, and association leaders.

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, November 6, 2023
Neoplasm, SERM, CD3, EVOLVE, Breast, Therapy, ULBP2, SERD, Salk Institute for Biological Studies, Immunology, Research, Selective estrogen receptor degrader, SITC, B7-H4, Immunotherapy, Estrogen receptor, Cancer, Triple-negative breast cancer, Breast cancer, TNBC, Society, Patient, CD2, Vaccine, Pharmaceutical industry

In addition, presented data highlighted the robust anti-tumor efficacy exhibited by lead molecules for the EV-104 and EV-106 programs in patient-derived solid tumor models.

Key Points: 
  • In addition, presented data highlighted the robust anti-tumor efficacy exhibited by lead molecules for the EV-104 and EV-106 programs in patient-derived solid tumor models.
  • The EVOLVE platform uniquely unleashes potent, selective and integrated T cell costimulation, which amplifies and sustains the tumor killing capacity of these T cells.
  • The platform also takes advantage the company’s understanding of specific tumor cell characteristics to guide tumor antigen prioritization and program differentiation.
  • In a poster presentation at SITC, EvolveImmune spotlighted advances to the company’s first-in-class EV-104 program, a novel multi-functional T cell engager with integrated CD2 costimulation which conditionally targets ULBP2.

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Wednesday, October 18, 2023
EVOLVE, Regulation, Impact, Research, SITC, B7-H4, Immunotherapy, Yale Cancer Center, Tumor microenvironment, Immunology, Society, Cancer, Therapy, Patient, CD2, Neoplasm, Vaccine

BRANFORD, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today announced that new preclinical and translational data highlighting EVOLVE, the company’s novel costimulatory T cell engager platform, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California. The poster presentations will unveil the company’s pioneering insights into the impact of tumor lineages on tumor antigen expression and immune infiltration in the tumor microenvironment. These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.

Key Points: 
  • These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.
  • The EVOLVE platform uniquely unleashes potent, selective and integrated T cell costimulation, which amplifies and sustains the tumor killing capacity of these T cells.
  • In two poster presentations, EvolveImmune will highlight how the differentiated aspects of the EVOLVE platform are being applied to two solid tumor programs, EV-104 and EV-106.
  • By supplying this second costimulatory signal to T cells, their cancer killing capacity is both heightened and prolonged.